The Modern Agriculture Foundation is delighted to invite you to
Alternative Proteins IL 2020 Technology Seminar

Alternative Proteins IL 2020 is a full-day technology seminar, connecting professionals from the worlds of Alternative Protein, Pharma, Biotech and other life science industries, to foster learning, inspiration and future collaborations.

* More details will be published soon.
* The Seminar is taking place after the Jewish High Holidays national lockdown. We are following all changes and act in accordance with instructions from the Ministry of Health. If needed, the event will be held online or postponed.

For seminar announcements, updates, and Alternative Protein news, join us:
First Speakers Announced
Prof. Yaakov Nahmias
Founder & CSO, Tissue Dynamics
Founder & CSO, Future Meat Technologies

Professor of Bioengineering, The Hebrew University of Jerusalem (HUJI)

Prof. Yaakov “Koby” Nahmias is a bioengineer and innovator, whose breakthroughs ranged from the first 3D printing of cells to the first commercial human-on-chip technology. He is a Magna Cum Laude graduate of the Technion, Israel Institute of Technology, and is the founding director of the Grass Center for Bioengineering of the Hebrew University of Jerusalem. Nahmias is a recipient of a NIH career award, two European Research Council (ERC) grants, the Kaye Innovation Award and the prestigious Rappaport Prize in Biomedical Research. He is the first scientist outside Britain to win the Rosetrees Trust Prize. Nahmias is the co-founding director of BioDesign-Israel. An entrepreneurship program that educated over 120 fellows, raising $3M in investment and 10 startup companies including Guide In Medical, CardioVia and VenoVision. Nahmias is the founder and CSO of two biotechnology startups, including Tissue Dynamics that is developing a groundbreaking human-on-chip instruments for drug development, and the Tyson Foods-funded Future Meat Technologies focusing on the cost-effective production of cultured meat.
Gero Greive
Head of Process Engineering, Bioengineering
Gero Greive is Head of Process Engineering at Bioengineering, a Swiss company that has designed and fabricated benchtop-scale research bioreactors to commercial production plants in Israel and around the world for biopharmaceutical, food and fine chemical applications. Prior to that, Gero has worked as project manager and process engineer for the upscaling, engineering and execution of turnkey projects that include some of the largest operational mammalian cell culture bioreactors today with capacities upwards of 20’000L. In addition, he has lead Bioengineering’s R&D team for continuous process systems (HTST, Dilution and perfusion) and process simulations (Liquid and Gas CFD). Gero has a keen interest in cell-based alternative proteins and is working with cell-based meat, fish and fat companies to address upscaling challenges and usher in the next agricultural revolution.
Yael Himmel Shlomo
Director Of Regulatory Affairs, RS-NESS
As a Director of Regulatory Affairs, Yael brings to her role 10 years of industry experience in multi-disciplinary Medical Device companies. Yael is experienced in leading regulatory processes in companies in different stages, managing and mitigating risks, and carrying discussions with different regulatory agencies. In the past, she has held top-level manager roles in the Medical Device and In-Vitro Diagnostics companies. Yael graduated from The Hebrew University of Jerusalem with a B.Sc degree in Biology and a M.Sc. degree in Structural and Molecular Biochemistry.
Diana Gershtein, M.Sc, MBA
Advanced Therapies Section Manager, Gsap
Ms. Gershtein has over 15 years of diversified experience in the unique industry of Advanced Therapies (cellular, tissue and gene therapies), with a vast knowledge in product regulation, development, manufacturing and quality. Diana holds Master's degrees in Molecular Biology and Business Administration. At her former position at MGVS she was responsible for the company cellular and gene therapies manufacturing in Israel and USA, managing all aspects of a complex multi-center clinical-stage operation. During the last six years Ms. Gershtein is the Advanced Therapies Section Manager at Gsap, the leading consulting firm in the field, providing regulatory strategic advice on advancing product development, as well as practical guidance through pre-clinical and clinical stages, technology transfer to GMP manufacturing, quality assurance and regulatory affairs. Gsap has worked until today with more than 35 cellular and gene therapy companies in Israel and abroad, at different stages of product development, starting from early proof of concept to advanced stage clinical studies. In the last years Gsap is providing consultation services to cell-based and gene-modified products which are utilizing advanced manufacturing technologies, such closed automated systems and 3D Bioprinting.
Dr. Neta Lavon
Vice President of Research and Development, Aleph Farms
Dr. Lavon is an expert in stem cell applications in biotechnology. Throughout her 20 years of experience, she held the position of the COO at Kadimastem (KDST), where she developed cell therapy products for ALS and Diabetes patients. Previously, she worked as a researcher in Cedars-Sinai in Los Angeles, USA, and established 25 novel pluripotent stem cell lines. Dr. Lavon holds a PhD in Genetics, an M.Sc. in Biotechnology and a B.Sc. in Food Sciences from the Hebrew University, Israel.
Gali Artzi, PhD.
VP Innovation and Clinical Affairs, NPS, IFF
Gali is a seasoned innovation leader with a multidisciplinary background in biomedical research in both academia and industry. She managed medical team that provided medical/nutritional support, education and clinical guidance to commercial, marketing, and sales teams. Gali spearheaded projects and led organic pipeline innovation and external inorganic innovation to develop market-ready products. Today Gali leads IFF's Israel based Innovation hub, which multiple innovation platforms that create value for startups in Israel and abroad, and for IFF as a global innovation leader in the field of foodtech. As part of the innovation division Gali also leads clinical research that supports organic growth with the development of new research-based products. Gali holds a Ph.D. in cell immunology and biology from Tel Aviv University.

facebook icon youtube icon linkedin icon